Strategic Launch and Market Potential of Yutrepia Justifies Buy Rating for Liquidia Technologies

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $25.00.

Jason Gerberry has given his Buy rating due to a combination of factors including Liquidia Technologies’ strategic launch plans for Yutrepia and its potential market impact. The company is targeting a launch into two significant orphan markets by June 2025, with expectations to reach P&L break-even within three to four quarters post-launch. This optimistic outlook is supported by the anticipated peak sales of Yutrepia, estimated to reach around $1 billion, particularly driven by its role in expanding the ILD market segment.
Additionally, the pricing strategy for Yutrepia is set to be competitive, with a monthly list price aligned with that of a key competitor, Tyvaso. Despite the absence of comparative clinical data, the underlying PRINT technology of Yutrepia is expected to facilitate effective dosing, which could enhance efficacy outcomes. These factors, combined with a moderated initial launch ramp and controlled operating expenses, underpin Gerberry’s confidence in Liquidia’s growth prospects, justifying the Buy rating and a price objective of $25.

Gerberry covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Teva Pharmaceutical, and Liquidia Technologies. According to TipRanks, Gerberry has an average return of 2.2% and a 49.38% success rate on recommended stocks.

In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $37.00 price target.